Abstract | OBJECTIVE: STUDY DESIGN: Patients (n = 1215) >4 weeks of age from 33 Cystic Fibrosis Foundation accredited sites who had a sweat chloride >60 mmol/L or two CF-causing mutations were enrolled using a proportionate sampling strategy in a nonblinded study. Patients submitted a stool sample and completed a questionnaire. The study coordinator also completed a questionnaire for each patient. Enzyme dosing and growth, abdominal pain, gassiness, constipation, and number of stools were compared. RESULTS: Of the 1215 enrolled patients, 1131 (93.1%) were prescribed PET. Only 14.9% had pancreatic function assessed before enrolling in this study. Stool elastase-1 analysis identified 1074 (89%) patients as pancreatic insufficient (PI). There was no association between PET and the outcomes: growth, abdominal pain, gassiness, constipation, and number of stools. CONCLUSION: PET dose is not correlated with growth or gastrointestinal symptoms. More sensitive outcome measures of the effectiveness of PET in patients with CF are needed to guide treatment of PI.
|
Authors | Susan S Baker, Drucy Borowitz, Linda Duffy, Laura Fitzpatrick, Joyce Gyamfi, Robert D Baker |
Journal | The Journal of pediatrics
(J Pediatr)
Vol. 146
Issue 2
Pg. 189-93
(Feb 2005)
ISSN: 0022-3476 [Print] United States |
PMID | 15689904
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Abdominal Pain
(etiology)
- Adolescent
- Child
- Child, Preschool
- Constipation
(etiology)
- Cystic Fibrosis
(complications, drug therapy)
- Diarrhea
(etiology)
- Dose-Response Relationship, Drug
- Exocrine Pancreatic Insufficiency
(complications, drug therapy)
- Humans
- Infant
- Pancreas
(drug effects, physiopathology)
- Pancreatic Elastase
(therapeutic use)
- Pancreatic Function Tests
- Surveys and Questionnaires
- Treatment Outcome
|